keyword
MENU ▼
Read by QxMD icon Read
search

Leukemia mortality

keyword
https://www.readbyqxmd.com/read/29776868/hemorrhagic-cystitis-after-hematopoietic-stem-cell-transplantation-a-challenge-for-the-pediatric-urologist
#1
REVIEW
Romy Gander, Marino Asensio, Gabriela Guillén, Gloria Fatou Royo, Andrea Bolaños, Mercedes Pérez, Cristina Diaz-De-Heredia, Maribel Benitez, Manuel López
OBJECTIVE: Hemorrhagic cystitis (HC) is a serious event that can occur after hematopoietic stem cell transplantation (HSCT). Treatment goals are primarily to preserve life, and then the functionality of the bladder. There is no standard therapeutic approach for HC. Described treatment options provide low success rates and are related to potential life-threatening side effects. The aim of this study was to describe our experience in treatment of HC following HSCT. PATIENTS AND METHODS: This was a retrospective study of patients with HC treated at our institution between January 2010 and October 2016...
April 20, 2018: Journal of Pediatric Urology
https://www.readbyqxmd.com/read/29756724/stevens-johnson-syndrome-associated-with-methotrexate-treatment-for-acute-lymphoblastic-leukemia-a-case-report
#2
Burcu Akıncı, Zuhal Ö Siviş, Akkız Şahin, Deniz Y Karapınar, Can Balkan, Kaan Kavaklı, Yeşim Aydınok
Toxic epidermal necrolysis and Stevens-Johnson syndrome are rare mucocutaneous diseases which are associated with a prolonged course and potentially lethal outcome. They are mostly drug induced and mortality rates are very high. Although mostly skin is involved, multiple organ systems such as cardiovascular, pulmonary, gastrointestinal, and urinary systems may be affected. Here, we report a case of Stevens- Johnson Syndrome associated with methotrexate treatment who developed acute cardiac failure and gastrointestinal hemorrhage beside skin findings...
June 1, 2018: Archivos Argentinos de Pediatría
https://www.readbyqxmd.com/read/29755802/cytomegalovirus-colitis-masquerading-as-apple-core-lesion-after-systemic-chemotherapy-in-a-patient-with-relapsed-acute-myeloid-leukemia
#3
Jong An, Jason Brownell, Darrell Barker, Theresa Stockinger, Robert Brady, Katherine Cebe, Russell Baur
We report the case of a 71-year-old male with relapsed acute myeloid leukemia who developed cytomegalovirus (CMV) colitis presenting as an apple-core lesion during induction chemotherapy. CMV infection occurs rarely during induction chemotherapy for acute myeloid leukemia. CMV infection is usually observed in patients with acquired immune deficiency syndrome (AIDS) and in those on immunosuppressive agents following bone marrow transplant. Although rare, CMV colitis should be considered in patients who are critically ill after systemic chemotherapy as it can cause significant morbidity and mortality...
2018: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/29753157/treosulfan-fludarabine-and-low-dose-total-body-irradiation-for-children-and-young-adults-with-acute-myeloid-leukemia-or-myelodysplastic-syndrome-undergoing-allogeneic-hematopoietic-cell-transplantation-a-prospective-phase-ii-trial-of-the-pediatric-blood-and
#4
Eneida R Nemecek, Ralf A Hilger, Alexia Adams, Bronwen E Shaw, Deidre Kiefer, Jennifer Le-Rademacher, John E Levine, Gregory Yanik, Wing Leung, Julie-An Talano, Paul Haut, David Delgado, Neena Kapoor, Aleksandra Petrovic, Roberta Adams, Rabi Hanna, Hemalatha Rangarajan, Jignesh Dalal, Joseph Chewning, Michael R Verneris, Stacy Epstein, Lauri Burroughs, Evelio D Perez-Albuerne, Michael A Pulsipher, Colleen Delaney
This multicenter study evaluated a treosulfan-based regimen in children and young adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). Forty patients with median age 11 years (1-19) underwent allogeneic HCT for AML in first (n=18), second (n=11), third or greater remission (n=3); or MDS (n=8) using bone marrow (n=25), peripheral blood stem cells (n=5) or cord blood (n=9). The regimen consisted of body surface area (BSA)-based treosulfan 10 g/m2 /day (BSA ≤ 0...
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29751115/evaluation-of-histocheck-as-a-predictor-of-clinical-outcomes-after-haploidentical-hematopoietic-stem-cell-transplantation
#5
Ming-Rui Huo, Dan Li, Ying-Jun Chang, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is available for nearly all patients without matching human leukocyte antigen (HLA) related or unrelated donors. There was not a valid evaluation system to predict the most proper donor. HistoCheck was based on the functional similarity of amino acids to estimate the allogenicity of HLA mismatches with a sequence similarity matching (SSM) score. We investigated whether HistoCheck could predict clinical outcomes in 500 patients with acute leukemia or myelodysplastic syndrome receiving haplo-HSCT...
May 8, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29750747/haploidentical-donor-transplantation-using-a-novel-clofarabine-containing-conditioning-regimen-for-very-high-risk-hematologic-malignant-neoplasms
#6
Akshay Sharma, Guolian Kang, Anusha Sunkara, Hiroto Inaba, Sima Jeha, Shane J Cross, Terrence Geiger, Brandon Triplett
Recurrent/refractory hematologic malignancies have a poor prognosis, and there is a need for novel treatment regimens that can be tolerated by this heavily pretreated patient group. Clofarabine has antileukemic activity with an acceptable toxicity profile. In a phase I clinical trial (NCT00824135), we substituted clofarabine for fludarabine in a well-established reduced-intensity conditioning regimen for a T cell-depleted, mismatched-related (haploidentical) donor transplant backbone and explored the maximum tolerated dose of clofarabine in this combination in 15 patients undergoing hematopoietic cell transplantation for recurrent/refractory or secondary leukemia...
May 10, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29749432/roles-of-stat3-in-leukemia-review
#7
Yin Shi, Zhen Zhang, Xintao Qu, Xiaoxiao Zhu, Lin Zhao, Ran Wei, Qiang Guo, Linlin Sun, Xunqiang Yin, Yunhong Zhang, Xia Li
Leukemia is a type of hematopoietic malignancy, and the incidence rate in the United States and European Union increases by an average of 0.6 to 0.7% annually. The incidence rate in China is approximately 5.17/100,000 individuals, and the mortality rate is 3.94/100,000 individuals. Leukemia is the most common tumor affecting children and adults under 35 years of age, and is one of the major diseases leading to the death of adolescents. Signal transducer and activator of transcription 3 (STAT3) is a vital regulatory factor of signal transduction and transcriptional activation, and once activated, the phosphorylated form of STAT3 (p-STAT3) is transferred into the nucleus to regulate the transcription of target genes, and plays important roles in cell proliferation, differentiation, apoptosis and other physiological processes...
April 30, 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29749344/usefulness-of-cancer-free-survival-in-estimating-the-lifetime-attributable-risk-of-cancer-incidence-from-radiation-exposure
#8
Songwon Seo, Dal Nim Lee, Young-Woo Jin, Won Jin Lee, Sunhoo Park
Risk projection models estimating the lifetime cancer risk from radiation exposure are generally based on exposure dose, age at exposure, attained age, gender, and study population-specific factors, such as baseline cancer risks and survival rates. Because such models have been mostly based on the Life Span Study cohort of Japanese atomic bomb survivors, the baseline risks and survival rates in the target population should be considered when applying the cancer risk from Japanese atomic bomb survivors. The survival function used in risk projection models that are commonly used in radiological protection field to estimate cancer risk from medical or occupational exposure is based on all-cause mortality...
May 11, 2018: Journal of Radiological Protection: Official Journal of the Society for Radiological Protection
https://www.readbyqxmd.com/read/29748438/outcomes-of-hematopoietic-stem-cell-transplantation-from-unmanipulated-haploidentical-versus-matched-sibling-donor-in-patients-with-acute-myeloid-leukemia-in-first-complete-remission-with-intermediate-or-high-risk-cytogenetics-a-study-from-the-acute-leukemia
#9
Dalila Salvatore, Myriam Labopin, Annalisa Ruggeri, Giorgia Battipaglia, Ardeshir Ghavamzadeh, Fabio Ciceri, Didier Blaise, William Arcese, Gerard Socié, Jean Henri Bourhis, Mariateresa Van Lint, Benedetto Bruno, Anne Huynh, Stella Santarone, Eric Deconinck, Mohamad Mohty, Arnon Nagler
Allogeneic hematopoietic stem cell transplantation is the optimal care for patients with high-risk or intermediate acute myeloid leukemia. In patients lacking matched sibling donor, haploidentical donors are an option. We compared outcomes of unmanipulated haploidentical to matched sibling donor transplant in acute myeloid leukemia patients in first complete remission. Included were int- and high-risk acute myeloid leukemia in first complete remission undergoing haploidentical and matched sibling donor transplant from 2007-2015 and reported to the ALWP of the EBMT...
May 10, 2018: Haematologica
https://www.readbyqxmd.com/read/29743403/-role-of-anti-ccr4-antibody-in-the-treatment-of-transplant-eligible-patients-with-aggressive-adult-t-cell-leukemia-lymphoma
#10
Shigeo Fuji
Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell lymphoma caused by the human T-cell lymphotropic virus type I. Patients with aggressive ATL show dismal prognoses, even with intensive dose-dense chemotherapy. Such patients often show chemo-refractoriness. Mogamulizumab (Moga) is a potent treatment option for patients with relapsed or refractory ATL. However, use of Moga before allo-HSCT could theoretically increase the risk of post-transplant complications like graft-versus-host disease (GVHD) as Moga depletes regulatory T-cells (Tregs)...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29742278/conditional-relative-survival-among-long-term-survivors-of-adolescent-and-young-adult-cancers
#11
Chelsea Anderson, Andrew B Smitherman, Hazel B Nichols
BACKGROUND: Many studies have examined long-term outcomes after childhood cancer, but few address outcomes for adolescent and young adult (AYA; those aged 15-39 years) cancer survivors. Conditional survival reflects changing mortality risk with time since cancer diagnosis and is a useful measure for planning long-term follow-up care. METHODS: Using the Surveillance, Epidemiology, and End Results registry 9 database, the authors identified a cohort of AYA patients diagnosed with a first malignant cancer between 1973 and 2009 and followed through 2014...
May 9, 2018: Cancer
https://www.readbyqxmd.com/read/29739773/graft-versus-host-disease-in-recipients-of-male-unrelated-donor-compared-with-parous-female-sibling-donor-transplants
#12
Anita J Kumar, Soyoung Kim, Michael T Hemmer, Mukta Arora, Stephen R Spellman, Joseph A Pidala, Daniel R Couriel, Amin M Alousi, Mahmoud D Aljurf, Jean-Yves Cahn, Mitchell S Cairo, Corey S Cutler, Shatha Farhan, Usama Gergis, Gregory A Hale, Shahrukh K Hashmi, Yoshihiro Inamoto, Rammurti T Kamble, Mohamed A Kharfan-Dabaja, Margaret L MacMillan, David I Marks, Hideki Nakasone, Maxim Norkin, Muna Qayed, Olle Ringden, Harry C Schouten, Kirk R Schultz, Melhem M Solh, Takanori Teshima, Alvaro Urbano-Ispizua, Leo F Verdonck, Robert Peter Gale, Betty K Hamilton, Navneet S Majhail, Alison W Loren
Optimal donor selection is critical for successful allogeneic hematopoietic cell transplantation (HCT). Donor sex and parity are well-established risk factors for graft-versus-host disease (GVHD), with male donors typically associated with lower rates of GVHD. Well-matched unrelated donors (URDs) have also been associated with increased risks of GVHD as compared with matched sibling donors. These observations raise the question of whether male URDs would lead to more (or less) favorable transplant outcomes as compared with parous female sibling donors...
May 8, 2018: Blood Advances
https://www.readbyqxmd.com/read/29734957/hospital-level-variability-in-broad-spectrum-antibiotic-use-for-children-with-acute-leukemia-undergoing-hematopoietic-cell-transplantation
#13
Caitlin W Elgarten, Staci D Arnold, Yimei Li, Yuan-Shung V Huang, Marcie L Riches, Jeffrey S Gerber, Richard Aplenc, Wael Saber, Brian T Fisher
OBJECTIVETo explore the prevalence and drivers of hospital-level variability in antibiotic utilization among hematopoietic cell transplant (HCT) recipients to inform antimicrobial stewardship initiatives.DESIGNRetrospective cohort study using data merged from the Pediatric Health Information System and the Center for International Blood and Marrow Transplant Research.SETTINGThe study included 27 transplant centers in freestanding children's hospitals.METHODSThe primary outcome was days of broad-spectrum antibiotic use in the interval from day of HCT through neutrophil engraftment...
May 8, 2018: Infection Control and Hospital Epidemiology
https://www.readbyqxmd.com/read/29731847/blue-light-induced-apoptosis-of-human-promyelocytic-leukemia-cells-via-the-mitochondrial-mediated-signaling-pathway
#14
Jianjian Zhuang, Yange Liu, Qingxia Yuan, Junsong Liu, Yan Liu, Hongdong Li, Di Wang
Acute promyelocytic leukemia is frequently associated with dizziness, fever, nausea, hematochezia and anemia. Blue light, or light with wavelengths of 400-480 nm, transmits high levels of energy. The aim of the present study was to determine the pro-apoptotic effects of blue light (wavelength, 456 nm; radiation power, 0.25 mW/cm2 ) and the underlying mechanisms in a human promyelocytic leukemia cell line (HL60). Blue light reduced the viability and enhanced the mortality of HL60 cells in a time-dependent manner...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29728701/ibrutinib-for-bridging-to-allogeneic-hematopoietic-cell-transplantation-in-patients-with-chronic-lymphocytic-leukemia-or-mantle-cell-lymphoma-a-study-by-the-ebmt-chronic-malignancies-and-lymphoma-working-parties
#15
Peter Dreger, Mauricette Michallet, Paul Bosman, Sascha Dietrich, Mohamad Sobh, Ariane Boumendil, Arnon Nagler, Christof Scheid, Jan Cornelissen, Dietger Niederwieser, Lutz Müller, Elizabeth Vandenberghe, Ilaria Scortechini, Helene Schoemans, Niels S Andersen, Jürgen Finke, Domenico Russo, Per Ljungman, Jakob Passweg, Michel van Gelder, Nadira Durakovic, Helene Labussiere-Wallet, Tobias Berg, Gerald Wulf, Wolfgang Bethge, Donald Bunjes, Stefan Stilgenbauer, Maria Elisa Canepari, Michel Schaap, Christopher P Fox, Nicolaus Kröger, Silvia Montoto, Johannes Schetelig
The aim of this retrospective study was to investigate the safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible were patients aged >18 years allotransplanted for chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) after prior exposure to ibrutinib who were registered with the EBMT registry. Seventy patients (CLL 48, MCL 22) were included. At the time of alloHCT, 73% of the patients were ibrutinib responsive. All patients except one engrafted, and acute GVHD grade 2-4 (3-4) was observed in 49% (12%) of 68 evaluable patients...
May 4, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29726788/outcomes-in-obese-patients-undergoing-induction-therapy-for-acute-leukemia
#16
Lauren Dombrowski, Leila Mohassel
Obesity continues to be a growing epidemic in the United States. Guidelines published by American Society of Clinical Oncology in 2012 recommend dosing chemotherapy using actual body weight. However, the guidelines do not provide guidance for patients with hematologic malignancies. The objective of this study was to evaluate outcomes in obese patients undergoing induction chemotherapy for acute leukemia versus nonobese patients using actual body weight dosing. This single center retrospective chart review from November 2012 to August 2016 evaluated newly diagnosed leukemia patients who received induction chemotherapy dosed on actual body weight...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29725549/fusarium-endophthalmitis-unusual-and-challenging-infection-in-an-acute-leukemia-patient
#17
Mehmet Baysal, Elif Umit, İbrahim Bekir Boz, Onur Kırkızlar, Muzaffer Demir
Invasive fungal infections bring serious mortality and morbidity during the treatment of acute myeloid leukemia. Especially, mold infections are challenging, and each case is unique in feature. These cases are usually fatal, and there is no consensus regarding optimal treatment. AML patients receive antifungal prophylaxis and may further require IFI (invasive fungal infection) treatments, but fusarium mold infections are often unrecognized and could be overlooked. In this case report, we try to emphasize the importance of this infection with a high-risk AML patient...
2018: Case Reports in Hematology
https://www.readbyqxmd.com/read/29725413/expression-levels-of-the-runt-related-transcription-factor-1-and-3-genes-in-the-development-of-acute-myeloid-leukemia
#18
Adrian Krygier, Dagmara Szmajda, Marta Żebrowska, Agnieszka Jeleń, Ewa Balcerczak
The aim of the present study was to evaluate the mRNA expression level of the runt-related transcription factor 1 ( RUNX1 ) and runt-related transcription factor 3 ( RUNX3 ) genes in patients with acute myeloid leukemia (AML). The etiology of AML is not yet fully known, but certain genetic factors may contribute to its manifestation. The RUNX1 and RUNX3 genes have been demonstrated to serve a role in the transcription process. The group investigated in the present study included 43 patients diagnosed with AML, and the relative RUNX1 and RUNX3 expression levels were determined using reverse transcription-quantitative polymerase chain reaction...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29724543/fusarium-solani-infection-as-an-initial-manifestation-of-aml-transformation-in-myelodysplastic-syndrome-a-case-report
#19
D P Borges, A W A Santos, S M M Magalhaes, J J Sidrim, M F G Rocha, R A Cordeiro, R S N Brilhante, S P Bandeira, J T Valença Junior, R F Pinheiro
Severely immunocompromised patients are at increased risk for uncommon infectious diseases with atypical presentations. Fusarium sp., has been reported in patients with hematological malignancies and prompt diagnosis is necessary due to high mortality. We report a myelodysplastic syndrome (MDS) patient who presented Fusarium solani infection associated with granulocytic sarcoma as an initial presentation of acute myeloid leukemia (AML) transformation. We performed histological examination, immunohistochemistry analysis, culture of the biopsy tissue and DNA sequencing to make a conclusive diagnosis of F...
April 30, 2018: Journal de Mycologie Médicale
https://www.readbyqxmd.com/read/29720734/phase-1-2-trial-of-gclam-with-dose-escalated-mitoxantrone-for-newly-diagnosed-aml-or-other-high-grade-myeloid-neoplasms
#20
Anna B Halpern, Megan Othus, Emily M Huebner, Bart L Scott, Pamela S Becker, Mary-Elizabeth M Percival, Paul C Hendrie, Kelda M Gardner, Tara L Chen, Sarah A Buckley, Kaysey F Orlowski, Asma Anwar, Frederick R Appelbaum, Harry P Erba, Elihu H Estey, Roland B Walter
Outcomes with "7 + 3" are often unsatisfactory in acute myeloid leukemia (AML). Trials demonstrating improved outcomes with high-dose cytarabine, addition of cladribine, or escalated anthracycline doses prompted a phase 1/2 study (NCT02044796) of G-CSF, cladribine, high-dose cytarabine, and dose-escalated mitoxantrone (GCLAM) in adults with newly-diagnosed AML or other high-grade myeloid neoplasms. One hundred and twenty-one patients, median age 60 (range 21-81) years, were enrolled. In phase 1, cohorts of 6-12 patients were assigned to 12-18 mg/m2 /day of mitoxantrone as part of GCLAM...
April 17, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
keyword
keyword
58219
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"